HUE030158T2 - Glükopiranozil-csoporttal szubsztituált benzolszármazékot tartalmazó gyógyászati készítmény - Google Patents
Glükopiranozil-csoporttal szubsztituált benzolszármazékot tartalmazó gyógyászati készítmény Download PDFInfo
- Publication number
- HUE030158T2 HUE030158T2 HUE08787264A HUE08787264A HUE030158T2 HU E030158 T2 HUE030158 T2 HU E030158T2 HU E08787264 A HUE08787264 A HU E08787264A HU E08787264 A HUE08787264 A HU E08787264A HU E030158 T2 HUE030158 T2 HU E030158T2
- Authority
- HU
- Hungary
- Prior art keywords
- pharmaceutical composition
- dpp
- inhibitor
- glucose
- glucopyranosyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Claims (6)
- Glüköpiras*«#i!»i\«.oporttal szniwmnmlí heaz o tsz ár?ív^^ekot tartalmazó gyógyászati készítmény1, GyógyászaU készítmény, amely az Gkk'>r-4-(p-D-gItík.opifanoZ“l“íl}'"2~l4*({S)-4ítrahidrofuran-341~oxi t-henzi 1Mnmzd elitevfiásó, glükopiranozil-csoporftal szuhszti-\XVMé benzolszármazékot 1 -|{4-meUbktnazGll»||4i)-i»odUAi-mettt-?-<2-hutin- 1 -11)--8^3- (I^annmj-píperiiiínG-ítyxantm ehsgvezéső PfpvIV-mhtMtprml vagy aapil győgyár szatiiag elfogadható sójával együtt tartalmazza.
- 2. Az 1 . igénypont szerinti gyógyászati készítmény, azzal jellemezve, hogy alkalmas a glükoplnmozü-osopürttal szubsztitnált benzolszármazék és a DFF-IY-lpMfeltor kombinálj egytdajd vagy egymást követő alkalmazáséra, X Az elérő igénypontok egyike szerinti gyógyászati ké.vzüméoY, azzal jellemezve* bogy a glUkopiranozif-csoporttól sztfoaztifollt benzélsAínazék és a OFF-I¥-inMligtf egyetlen dózisainkban van lelete
- 4. Az előző Igénypontok egyike szerinti gyógyászati készítmény, azzal jellemezve, hogy a gfokopirattoxil-esoporttal szttbsztua|t|é^^ólP.^FI^l .<$1 I IMP^I^^IiFÍFt:tpr: külőn-kíüün dózisainkban van jelen,
- 5, Az előző igénypontok egyike szerinti gyógyászati készítmény, azzal jellemezve, bogs 5 ¥ m„ méta 'isegts. glukopttanorP-v vg > í ti < t\ fom ol- , tM\'*ot őartalmaz* ó, Az 5, Igénypont szerinti gyógyászati készítmény* amely $ mg, lü mg, lő mg, 211 mg, 2$ mg vagy 50 mg mennyiségé, glükoptranozii-csoporttal szubszdtuáli benzol-azat mázokot uatafo-az % Az előző igén} pontok egyike szerinti gyógyászati készítmény, amely 0,S-1Ö mg mennyiségű DPP-IV ·inhibitort tartalmaz. S. A ?. igénypont szerinti gyógyászati 2,5 mg vagy 5 mg mennyiségű DPlMVbnbibUort tartalmaz, H M U 2., 3. vagy 4. igéa>*l· szerinti lyolpáiiaikiszimtény, amely 5-50 mg mennyiségik gItlkopua»ozíl-CM|Kí#al sm^É^iksált és 0,5-iö mg :Í3FI^I¥4|jl)|bi(ort tartalmaz.
- 10. Az előző iaérnpuTüok bármelyike szerinti gyógyászati készítmény, azzal jel-lemezve, hogy a gyógyászati készítmény óráim adagoláshoz alkalmas szilárd alakban von formuláivá, Π. Az 1 -1Ö. igénypontok: egyike sprfnti gyógyászati készítmény a következőkre jförténő alkalmazásra. * 3 kővetkezőkből álló csoportból kiválasztott anyagesere-rerdelienesség megélő-mse, kodem tőse ke <. 0-, - elmdvf adá\mvd ,^se i\5 Aon t'pirm oakorhetegseg, 2-es típusú cukorbetegség, csökkent ghlkőzmleranda, emel keddit éhomi véretikőrszlní, hipergtikémia, étkezés után* hlpergiikémla. túlsúly* dliizás #· mátitmlllöi' MlMlfÉípá; vagy - vércukorszím-szabályozás javítása és/vagy az éhomi plena^gltlké^zinteaz étkezős utam plaznm deké/sznaéa sags a üb\le glikoztlált hetnogiobin agatticnck esők-kerítése, vagy - csökkent glükóztól «randa, érnelkédett éhem! vli^ ésA agy anyagcsere-szindrőmá állapotából 2-es típusú cukorbetegség állapotába történő előrehaladás megelőzése, láátl%P késleltetése vagy visszaÉrrtlItásayyngy - a eokorhetegseg komplikációiból túgymuü a szörkeMlyog, a mikro- és; makro-vaszkuláris betegségek, mint például a nephropathia, retínopaihía, «európaiból, szövet-iseh-K?ttia. arteriosclerosis, szivizosniniarktus, stroke és perifériás arteries elzáródásom beiegség) álléíésoportbói :kAI!:ásziöttsál|á|mt;: vágy readfölleneasé|rtúegelőzése, kéaldté-tése, kezelése vagy előrehaladásának lassítása; vagy - iesisúiyesökkentés vagy testsúlynövekidés megelőzése vagy testsűiyesökkentés elősegítése; vagy - a hasnyálmirigy béta-sejtjei degenerációjának és/vagy a hasnyálmirigy béta-sejtjei működőképessége csökkenésének megdoeése. lassítása, késleltetése vagy kezdése és/vagy iá: basnyálmMgy feétaAéjitjei mfk^||pp|ÍPtiek javllüa és/vagy hearts állítass és vagy a «..sniatmingy maköA'keres nizuiin-szckiccmjának helyreállítását; vágy - a máj zsír rendellenes telhaimoződásával összefüggő betegségek vagy állapotok méplözéséziasiiítása, késidteiÉsö vagy kezdése; vágy ·.*· az :fa£ül inérzékenység fenntartása és/vagy javítása es/vagy f hlgerisstliiéföiá Cs \.no> mzulntrezisztetavt sa oVwtagy megelőzése', egy, a fenti beavatkozási ok lm rásKorutó pádeosben, 12, A 11, igértypont szerinti gyógyászait készítmény vércukorá^jny-mibályosás jr^ Vitására történő a *<ιΙ*"*ία>«',e- upuvn cxáorknegsőgK-u' vm * do lucartrtekfem. \' A 1 1, vagy 12, igény posst szermű gyógyászati kdvnntény az igényelt alkat* utazásra, azzal jellemezve, hogy a glükopiranozH-csopomai saubsztintált benzolszármazékot a DPP-IY-inhibitorral kombinálva vagy azzal feh állva adagoljuk, li. A ll,, O '<i«' Π geovoztíiXi ϊ ipog'tst-au kee/itjve*'N igenyelt oJka. mazásra, ahol a páciens a kivetkező csoportból kiválasztott egy xagy több állapottal diagnosztizált egyén: túlsúly, elhízás, zsigeri tipusü. elhízMMhasi tipusó elhízás. tő \ U.< 12 sags 13 tgen>pont s/enoíi gyogv^som készítmény ,v m\tneh alLA mazásra, ahol a páciens olyan szentély, akire a kivetkező állapotok közül egy, kettő vagy több jellemző: |a) 110 mg/dl-nd nagplbbgklzáíebbrik 121 mg/di-nÉI: n^ólií#ömi'vi^|j^fe vagy szérum gíükóz-koneentráció; {b) H0 rng/dí vagy nagyobb étkezés utéMplazma glOkóz-koncenirácíő; (c) 6,5 % vagy nagyobb, közelebbről, 8,0 % vagy nagyobb HbA lekérték, lü, Λ U,> 12 vagy 13 igénypont szerinti gyógyászati. készmnéns uz igényelt aikab raazásra, ahol a páciens olyan személy, akire a következő állapotok- közül egy, kettő vagy több jellemző: (a? elhízás, zsigeri típusú elhízás és/vagv hasi típusú elhízás, (b) 150 mg/dl vagy nagyobb vér trigíkerid-szmt, (e) nőknél 40 mg/dl-né! kisebb, férfiaknál 50 mgúll-nél kisebb vér HDL-koleszzerinszim, (d) 130 Hgrnm vagy nagyobb szbztolés vérnyomás 85 Hgmm vagy nagyobb diasz*. Oils vérnyomás, (e) 1 lOmg-'dl vagy nagyobbéhoroi vérglükózsaánt. I?. A 11,, 12. vagy lő. igénypont szerinti gyógyászati készítmény az igenyelt alkalmazásra, ahol a páciens olyan személy, akinél a otetformimtal vegzou monorerápia el- Itn|aval3í ésAPgy aÉ! a u apu*\ 4o w^u' *<e»fny»c«&é>· »r *tat> IS, A 11., 12. vagy 13, Igénypont szermii gyógyászati készítmény az igényelt alkal* mazásra, ahol a páciens olyan személy, akiben a vércukotsztat-szafeályozás egy SGLT2-mhiixUomé. közckbbröL az 1. igénypont szerinti, gíükopiraaoztl<soporual szubszíitnált benzolszármazékkal végzett muatnerápta ellenére elégtelen.
- 19. A Π,, 12, \ap> 13. igénypont szeműt gségsavout Keá/itmém a - tgemeíi elkel' mazasra. ahol a páciens olyan személy, akiben a véreuk>.írsz!nkszabályoáns égy OltSr I V-inbibitorrak közelebbről, az 1. igénypont szerinti Dl^-IY-ínhibitorral végzett mono-terápia ellenére elégtelen.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07114459 | 2007-08-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE030158T2 true HUE030158T2 (hu) | 2017-04-28 |
Family
ID=39870130
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE08787264A HUE030158T2 (hu) | 2007-08-16 | 2008-08-15 | Glükopiranozil-csoporttal szubsztituált benzolszármazékot tartalmazó gyógyászati készítmény |
HUS1700020C HUS1700020I1 (hu) | 2007-08-16 | 2017-05-10 | Glükopiranozil-csoporttal szubsztituált benzolszármazékot tartalmazó gyógyászati készítmény |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUS1700020C HUS1700020I1 (hu) | 2007-08-16 | 2017-05-10 | Glükopiranozil-csoporttal szubsztituált benzolszármazékot tartalmazó gyógyászati készítmény |
Country Status (39)
Country | Link |
---|---|
US (1) | US8551957B2 (hu) |
EP (4) | EP3939577A1 (hu) |
JP (1) | JP5595914B2 (hu) |
KR (1) | KR101491554B1 (hu) |
CN (3) | CN104353077A (hu) |
AR (2) | AR067970A1 (hu) |
AU (1) | AU2008288407B2 (hu) |
BR (1) | BRPI0815331B8 (hu) |
CA (1) | CA2696558C (hu) |
CL (1) | CL2008002427A1 (hu) |
CO (1) | CO6251239A2 (hu) |
CY (2) | CY1118308T1 (hu) |
DK (1) | DK2187879T3 (hu) |
EA (1) | EA018608B1 (hu) |
EC (1) | ECSP109977A (hu) |
ES (1) | ES2602748T3 (hu) |
HK (2) | HK1203351A1 (hu) |
HR (1) | HRP20170022T1 (hu) |
HU (2) | HUE030158T2 (hu) |
IL (1) | IL202886A (hu) |
LT (2) | LT2187879T (hu) |
MA (1) | MA31612B1 (hu) |
ME (1) | ME02573B (hu) |
MX (1) | MX2010001696A (hu) |
MY (1) | MY152037A (hu) |
NL (1) | NL300872I2 (hu) |
NO (1) | NO2017020I2 (hu) |
NZ (1) | NZ583242A (hu) |
PE (1) | PE20090938A1 (hu) |
PL (1) | PL2187879T3 (hu) |
PT (1) | PT2187879T (hu) |
RS (1) | RS55205B1 (hu) |
SI (1) | SI2187879T1 (hu) |
TN (1) | TN2010000073A1 (hu) |
TW (2) | TW201436798A (hu) |
UA (1) | UA100384C2 (hu) |
UY (1) | UY31296A1 (hu) |
WO (1) | WO2009022007A1 (hu) |
ZA (1) | ZA200909105B (hu) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
EP2295422A3 (de) * | 2004-03-16 | 2012-01-04 | Boehringer Ingelheim International GmbH | Glucopyranosylsubstituierte Benzolderivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
ATE491700T1 (de) * | 2005-09-08 | 2011-01-15 | Boehringer Ingelheim Int | KRISTALLINE FORMEN VON 1-CHLORO-4-(ß-D- |
PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
NO347644B1 (no) | 2006-05-04 | 2024-02-12 | Boehringer Ingelheim Int | Polymorfer |
CA2651519A1 (en) | 2006-06-06 | 2007-12-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
US8283326B2 (en) * | 2006-10-27 | 2012-10-09 | Boehringer Ingelheim International Gmbh | Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
CL2008002425A1 (es) * | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta. |
CL2008002427A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
EP2222639A1 (en) | 2007-11-21 | 2010-09-01 | Decode Genetics EHF | Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders |
EP2240028B1 (en) | 2007-12-06 | 2016-07-20 | Intra-Cellular Therapies, Inc. | Pyrazolopyrimidine-4,6-dione derivatives and their use as pharmaceutical |
AR071175A1 (es) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante |
PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
BRPI0916769A2 (pt) | 2008-07-15 | 2017-09-26 | Theracos Inc | derivados de benzilbenzeno deuterados e métodos de uso |
KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
MX2011002558A (es) | 2008-09-10 | 2011-04-26 | Boehringer Ingelheim Int | Terapia de combinacion para el tratamiento de diabetes y estados relacionados. |
US20200155558A1 (en) * | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
US20240148737A1 (en) * | 2008-10-16 | 2024-05-09 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
UY32177A (es) * | 2008-10-16 | 2010-05-31 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético |
MA32940B1 (fr) | 2008-12-06 | 2012-01-02 | Intra Cellular Therapies Inc | Composes organiques |
JP5813511B2 (ja) | 2008-12-06 | 2015-11-17 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
KR20110098730A (ko) | 2008-12-06 | 2011-09-01 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
US8865729B2 (en) | 2008-12-23 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Salt forms of a xanthine compound |
TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
AR075204A1 (es) * | 2009-01-29 | 2011-03-16 | Boehringer Ingelheim Int | Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2 |
CN104906582A (zh) * | 2009-02-13 | 2015-09-16 | 勃林格殷格翰国际有限公司 | 包含sglt2抑制剂、dpp-iv抑制剂和任选的另一种抗糖尿病药的药物组合物及其用途 |
UY32427A (es) | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
AU2016213789B2 (en) * | 2009-02-13 | 2018-01-18 | Boehringer Ingelheim International Gmbh | SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia |
MA33043B1 (fr) * | 2009-02-13 | 2012-02-01 | Boehringer Ingelheim Int | Inhibiteur sglt-2 pour le traitement du diabete sucre de type 1, du diabete sucre de type 2, d'une intolerance au glucose ou d'une hyperglycemie |
KR101921934B1 (ko) * | 2009-02-13 | 2018-11-26 | 베링거 인겔하임 인터내셔날 게엠베하 | 글루코피라노실 디페닐메탄 유도체를 포함하는 약제학적 조성물, 이들의 약제학적 용량형, 이들의 제조방법 및 환자에서의 개선된 당 조절을 위한 이들의 용도 |
KR20150046382A (ko) | 2009-04-16 | 2015-04-29 | 다이쇼 세이야꾸 가부시끼가이샤 | 제약 조성물 |
CA2775961C (en) | 2009-09-30 | 2017-11-07 | Boehringer Ingelheim International Gmbh | Method for the preparation of a crystalline form of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene |
EP2486029B1 (en) | 2009-09-30 | 2015-06-10 | Boehringer Ingelheim International GmbH | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives |
UY32919A (es) | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos |
AU2010323068B2 (en) | 2009-11-27 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
EP2368552A1 (en) * | 2010-03-25 | 2011-09-28 | Boehringer Ingelheim Vetmedica GmbH | 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(r)-amino-piperidin-1-yl]-xanthine for the treatment of a metabolic disorder of a predominantly carnivorous non-human animal |
WO2011138421A1 (en) | 2010-05-05 | 2011-11-10 | Boehringer Ingelheim International Gmbh | Combination therapy |
US9434730B2 (en) | 2010-05-31 | 2016-09-06 | Intra-Cellular Therapies, Inc. | PDE1 inhibitor compounds |
US9371327B2 (en) | 2010-05-31 | 2016-06-21 | Intra-Cellular Therapies, Inc. | PDE1 inhibitor compounds |
KR20190050871A (ko) | 2010-06-24 | 2019-05-13 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
EA023330B1 (ru) * | 2011-05-10 | 2016-05-31 | Сандоз Аг | Полиморфная форма бензоата линаглиптина |
US20130035298A1 (en) | 2011-07-08 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
KR101985384B1 (ko) | 2011-07-15 | 2019-06-03 | 베링거 인겔하임 인터내셔날 게엠베하 | 치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도 |
WO2013098775A1 (en) * | 2011-12-28 | 2013-07-04 | Dr. Reddy's Laboratories Limited | Improved process for preparation of pure linagliptin |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
EP2849755A1 (en) | 2012-05-14 | 2015-03-25 | Boehringer Ingelheim International GmbH | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
JP6374862B2 (ja) * | 2012-05-24 | 2018-08-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 自己免疫性糖尿病、特に、ladaの治療に使用するためのdpp−4阻害剤としてのキサンチン誘導体 |
PT2981269T (pt) | 2013-04-04 | 2023-10-10 | Boehringer Ingelheim Vetmedica Gmbh | Tratamento de distúrbios metabólicos em animais equinos |
CA2812519A1 (en) * | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US20160000816A1 (en) * | 2013-04-05 | 2016-01-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
CA2812016A1 (en) * | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
TR201901110T4 (tr) | 2013-04-05 | 2019-02-21 | Boehringer Ingelheim Int | Empagliflozinin terapötik kullanımları. |
US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
SI2986304T1 (sl) * | 2013-04-18 | 2022-04-29 | Boehringer Ingelheim International Gmbh | Farmacevtski sestavek, postopki za zdravljenje in njegove uporabe |
FI3862003T3 (fi) | 2013-12-17 | 2023-12-28 | Boehringer Ingelheim Vetmedica Gmbh | SGLT-2-ihibiittori käytettäväksi aineenvaihdutahäiriön hoidossa kissaeläimillä |
US9902751B2 (en) | 2013-12-30 | 2018-02-27 | Mylan Laboratories Limited | Process for the preparation of empagliflozin |
KR20220097538A (ko) * | 2014-01-23 | 2022-07-07 | 베링거잉겔하임베트메디카게엠베하 | 개과 동물에서 대사 장애의 치료 |
WO2015128453A1 (en) | 2014-02-28 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Medical use of a dpp-4 inhibitor |
MX2016012705A (es) | 2014-04-01 | 2016-12-16 | Boehringer Ingelheim Vetmedica Gmbh | Tratamiento de trastornos metabolicos en animales equinos. |
CN103965020B (zh) * | 2014-05-06 | 2015-09-09 | 启东东岳药业有限公司 | 制备5-碘-2-溴苄醇的方法 |
US9546175B2 (en) | 2014-08-07 | 2017-01-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
NZ728804A (en) | 2014-09-25 | 2022-10-28 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals |
JP6682621B2 (ja) | 2015-08-27 | 2020-04-15 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーBoehringer Ingelheim Vetmedica GmbH | Sglt−2阻害剤含む液体医薬組成物 |
MX2018011088A (es) * | 2016-03-16 | 2018-11-22 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende empagliflozina y sus usos. |
US10155000B2 (en) | 2016-06-10 | 2018-12-18 | Boehringer Ingelheim International Gmbh | Medical use of pharmaceutical combination or composition |
CN113056488B (zh) * | 2018-08-21 | 2023-10-24 | Dsm营养产品有限责任公司 | 寡糖组合物及其用于降低氨水平的使用方法 |
WO2020058095A1 (en) | 2018-09-19 | 2020-03-26 | Galenicum Health S.L.U. | Pharmaceutical compositions of empagliflozin |
CN115916197A (zh) | 2020-04-22 | 2023-04-04 | 拜耳公司 | 用于治疗和/或预防心血管和/或肾脏疾病的非奈利酮和sglt2抑制剂的组合 |
Family Cites Families (236)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3174901A (en) | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
NL167151C (nl) | 1971-04-09 | 1981-11-16 | Acf Chemiefarma Nv | Werkwijze ter bereiding van geneesmiddelen met anti-parasitaire werking op basis van halogeen bevatten- de 2,2'-methyleendifenolderivaten, alsmede werkwijze ter bereiding van deze geneeskrachtige verbindingen. |
NO154918C (no) | 1977-08-27 | 1987-01-14 | Bayer Ag | Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin. |
DE2758025A1 (de) | 1977-12-24 | 1979-07-12 | Bayer Ag | Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung |
DE2951135A1 (de) | 1979-12-19 | 1981-06-25 | Hoechst Ag, 6230 Frankfurt | Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
US4786755A (en) | 1985-06-03 | 1988-11-22 | Warner-Lambert Company | Diphenic acid monoamides |
US4602023A (en) | 1985-06-03 | 1986-07-22 | Warner-Lambert Company | Diphenic acid monoamides |
US4786023A (en) | 1987-08-19 | 1988-11-22 | Harris Leverett D | Drafting implement holder |
DE19616486C5 (de) | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
WO1998031697A1 (en) | 1997-01-15 | 1998-07-23 | Sankyo Company, Limited | Aryl c-glycoside compounds and sulfated esters thereof |
JP2002501889A (ja) | 1998-02-02 | 2002-01-22 | トラスティーズ オブ タフツ カレッジ | グルコース代謝を調節する方法、およびそれに関連する試薬 |
CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
US6613806B1 (en) | 1999-01-29 | 2003-09-02 | Basf Corporation | Enhancement of the efficacy of benzoylbenzenes |
KR100591585B1 (ko) | 1999-08-31 | 2006-06-20 | 깃세이 야쿠힌 고교 가부시키가이샤 | 글루코피라노실옥시피라졸 유도체, 그것을 함유하는 의약조성물 및 그 제조 중간체 |
US6515117B2 (en) * | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
ES2433476T3 (es) | 2000-01-21 | 2013-12-11 | Novartis Ag | Combinaciones que contienen inhibidores de la dipeptidilpeptidasa-IV y agentes 5 antidiabéticos |
JP4456768B2 (ja) | 2000-02-02 | 2010-04-28 | 壽製薬株式会社 | C−配糖体を含有する薬剤 |
US6627611B2 (en) | 2000-02-02 | 2003-09-30 | Kotobuki Pharmaceutical Co Ltd | C-glycosides and preparation of thereof as antidiabetic agents |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
GB0014969D0 (en) | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
JP2004502690A (ja) | 2000-07-04 | 2004-01-29 | ノボ ノルディスク アクティーゼルスカブ | 酵素dpp−ivのインヒビターである複素環式化合物 |
IL155071A0 (en) | 2000-09-29 | 2003-10-31 | Kissei Pharmaceutical | Glucopyranosyloxybenzylbenzene derivatives and medical compositions containing the same |
CA2429833A1 (en) | 2000-11-30 | 2002-06-06 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof |
CA2433090A1 (en) | 2000-12-27 | 2002-07-04 | Kyowa Hakko Kogyo Co., Ltd. | Dipeptidyl peptidase iv inhibitor |
PL209375B1 (pl) | 2000-12-28 | 2011-08-31 | Kissei Pharmaceutical | Pochodne glukopiranozyloksypirazolu, kompozycja farmaceutyczna zawierająca takie pochodne i zastosowanie tych pochodnych do wytwarzania kompozycji farmaceutycznej |
TWI255817B (en) | 2001-02-14 | 2006-06-01 | Kissei Pharmaceutical | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof |
CN100408579C (zh) | 2001-02-24 | 2008-08-06 | 贝林格尔英格海姆法玛两合公司 | 黄嘌呤衍生物,其制法及其作为药物组合物的用途 |
US6936590B2 (en) * | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
JP3698067B2 (ja) | 2001-03-30 | 2005-09-21 | Jsr株式会社 | 電子吸引性基および電子供与性基を有するモノマー、それを用いた共重合体、ならびにプロトン伝導膜 |
AU2002338643A1 (en) | 2001-04-10 | 2002-10-28 | Millennium Pharmaceuticals, Inc. | 68723, sodium/glucose cotransporter family members and uses therefor |
AU2002254567B2 (en) | 2001-04-11 | 2007-10-11 | Bristol-Myers Squibb Company | Amino acid complexes of C-aryl glucosides for treatment of diabetes and method |
KR20040015298A (ko) | 2001-06-27 | 2004-02-18 | 스미스클라인 비참 코포레이션 | 디펩티딜 펩티다제 억제제로서의 플루오로피롤리딘 |
DE60225556D1 (de) | 2001-07-03 | 2008-04-24 | Novo Nordisk As | Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes |
US6869947B2 (en) | 2001-07-03 | 2005-03-22 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
EP1432720A1 (en) | 2001-09-05 | 2004-06-30 | Bristol-Myers Squibb Company | O-pyrazole glucoside sglt2 inhibitors and method of use |
EP1463727A2 (en) | 2001-09-19 | 2004-10-06 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme dpp-iv |
WO2003031458A1 (en) | 2001-10-12 | 2003-04-17 | Dana-Farber Cancer Institute | Methods for synthesis of diarylmethanes |
DE50212771D1 (de) | 2001-10-17 | 2008-10-23 | Boehringer Ingelheim Pharma | Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung |
US6861440B2 (en) * | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
JP2005513165A (ja) | 2002-01-11 | 2005-05-12 | ノボ ノルディスク アクティーゼルスカブ | 糖尿病、高血圧、慢性心不全および体液貯留状態の治療のための方法および組成物 |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
WO2003090783A1 (fr) | 2002-04-26 | 2003-11-06 | Ajinomoto Co., Inc. | Agent preventif/remede pour diabete |
DE10231370B4 (de) | 2002-07-11 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
TWI254635B (en) | 2002-08-05 | 2006-05-11 | Yamanouchi Pharma Co Ltd | Azulene derivative and salt thereof |
NZ538117A (en) | 2002-08-08 | 2007-01-26 | Kissei Pharmaceutical | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
SI1532149T1 (sl) * | 2002-08-21 | 2010-05-31 | Boehringer Ingelheim Pharma | amino piperidin il ksantini njihova priprava in njihova uporaba kot zdravila |
DE10238470A1 (de) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
DE10238477A1 (de) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
US7482337B2 (en) | 2002-11-08 | 2009-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
DE10251927A1 (de) | 2002-11-08 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
JP3567162B1 (ja) | 2002-11-20 | 2004-09-22 | 日本たばこ産業株式会社 | 4−オキソキノリン化合物及びそのhivインテグラーゼ阻害剤としての利用 |
CA2470365C (en) | 2002-11-20 | 2011-05-17 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
DE10254304A1 (de) | 2002-11-21 | 2004-06-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
UY28103A1 (es) | 2002-12-03 | 2004-06-30 | Boehringer Ingelheim Pharma | Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos |
US7109192B2 (en) * | 2002-12-03 | 2006-09-19 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions |
JP4651934B2 (ja) | 2002-12-04 | 2011-03-16 | キッセイ薬品工業株式会社 | ベンジルフェノール誘導体、それを含有する医薬組成物およびその医薬用途 |
US7420079B2 (en) | 2002-12-09 | 2008-09-02 | Bristol-Myers Squibb Company | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof |
DE10258007B4 (de) | 2002-12-12 | 2006-02-09 | Sanofi-Aventis Deutschland Gmbh | Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
DE10258008B4 (de) | 2002-12-12 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
US7375213B2 (en) | 2003-01-03 | 2008-05-20 | Bristol-Myers Squibb Company | Methods of producing C-aryl glucoside SGLT2 inhibitors |
US8293751B2 (en) | 2003-01-14 | 2012-10-23 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
US7164015B2 (en) | 2003-02-27 | 2007-01-16 | Bristol-Myers Squibb Company | Non-cryogenic process for forming glycosides |
KR101001848B1 (ko) | 2003-03-14 | 2010-12-17 | 고토부키 세이야쿠 가부시키가이샤 | C-글리코시드 유도체 또는 이의 염, 및 이를 포함하는 의약 조성물 |
US7674486B2 (en) | 2003-05-14 | 2010-03-09 | Indus Biotech Pvt. Ltd. | Synergistic composition for the treatment of diabetes mellitus |
WO2005000860A2 (en) | 2003-06-03 | 2005-01-06 | The Regents Of The University Of California | Compositions and methods for treatment of disease with acetylated disaccharides |
JP2004359630A (ja) | 2003-06-06 | 2004-12-24 | Yamanouchi Pharmaceut Co Ltd | ジフルオロジフェニルメタン誘導体及びその塩 |
DE10327439A1 (de) | 2003-06-18 | 2005-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel |
DK1638970T3 (da) | 2003-06-20 | 2011-01-03 | Hoffmann La Roche | Pyrid (2, 1-A)-isoquinolinderivater som DPP-IV-inhibitorer |
JO2625B1 (en) | 2003-06-24 | 2011-11-01 | ميرك شارب اند دوم كوربوريشن | Phosphoric acid salts of dipeptidyl betidase inhibitor 4 |
DE602004017325D1 (de) | 2003-07-21 | 2008-12-04 | Smithkline Beecham Corp | (2s,4s)-4-fluor-1-ä4-fluor-beta-(4-fluorphenyl)-l-phenylalanylü-2-pyrrolidincarbonitril-p-toluolsulfonsäuresalz und wasserfreie kristalline formen davon |
WO2005012318A2 (en) | 2003-08-01 | 2005-02-10 | Janssen Pharmaceutica Nv | Substituted fused heterocyclic c-glycosides |
PT1651658E (pt) | 2003-08-01 | 2013-03-07 | Mitsubishi Tanabe Pharma Corp | Novos compostos que possuem actividade inibidora dirigida contra os transportadores dependentes do sódio |
JP4131216B2 (ja) | 2003-08-20 | 2008-08-13 | Jsr株式会社 | ポリアリーレンおよびその製造方法、ならびに高分子固体電解質およびプロトン伝導膜 |
US7375090B2 (en) | 2003-08-26 | 2008-05-20 | Boehringer Ingelheim International Gmbh | Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof |
CA2539032A1 (en) | 2003-08-26 | 2005-03-10 | Boehringer Ingelheim International Gmbh | Glucopyranosyloxy-pirazoles, drugs containing said compounds the use and production method thereof |
US20050085680A1 (en) | 2003-10-21 | 2005-04-21 | Joseph Auerbach | Method for industrial decontamination |
US7526806B2 (en) * | 2003-11-05 | 2009-04-28 | Cisco Technology, Inc. | Method and system for addressing intrusion attacks on a computer system |
KR20170005163A (ko) * | 2003-11-17 | 2017-01-11 | 노파르티스 아게 | 디펩티딜 펩티다제 ⅳ 억제제의 용도 |
DE10355304A1 (de) | 2003-11-27 | 2005-06-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
DE10359098A1 (de) | 2003-12-17 | 2005-07-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-(Piperazin-1-yl)- und 2-([1,4]Diazepan-1-yl)-imidazo[4,5-d]pyridazin-4-one, deren Herstellung und deren Verwendung als Arzneimittel |
DE10361133A1 (de) | 2003-12-22 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Glucopyranosyloxy-substituierte Aromaten, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US7371732B2 (en) | 2003-12-22 | 2008-05-13 | Boehringer Ingelheim International Gmbh | Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture |
DE10360835A1 (de) | 2003-12-23 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel |
EP2165703A3 (en) | 2004-01-20 | 2012-03-28 | Novartis Pharma AG | Direct compression formulation and process |
EA010854B1 (ru) | 2004-02-18 | 2008-12-30 | Бёрингер Ингельхайм Интернациональ Гмбх | 8-[3-аминопиперидин-1-ил]ксантины, их получение и их применение в качестве ингибиторов dpp-iv |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004008112A1 (de) * | 2004-02-18 | 2005-09-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel |
DE102004009039A1 (de) | 2004-02-23 | 2005-09-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel |
KR101141558B1 (ko) | 2004-03-04 | 2012-05-03 | 깃세이 야쿠힌 고교 가부시키가이샤 | 축합 복소환 유도체, 그것을 함유하는 의약 조성물 및 그의약 용도 |
JP5078350B2 (ja) | 2004-03-04 | 2012-11-21 | キッセイ薬品工業株式会社 | 縮合ヘテロ環誘導体、それを含有する医薬組成物およびその医薬用途 |
CN102127053A (zh) * | 2004-03-15 | 2011-07-20 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
EP2295422A3 (de) * | 2004-03-16 | 2012-01-04 | Boehringer Ingelheim International GmbH | Glucopyranosylsubstituierte Benzolderivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
EP1740589A1 (de) | 2004-04-10 | 2007-01-10 | Boehringer Ingelheim International GmbH | Neue 2-amino-imidazo[4,5-d]pyridazin-4-one und 2-amino-imidazo[4,5-c]pyridin-4-one, deren herstellung und deren verwendung als arzneimittel |
US7741082B2 (en) | 2004-04-14 | 2010-06-22 | Bristol-Myers Squibb Company | Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor |
DE102004022970A1 (de) | 2004-05-10 | 2005-12-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazolderivate, deren Herstellung und deren Verwendung als Intermediate zur Herstellung von Arzneimitteln und Pestiziden |
GEP20084421B (en) | 2004-05-12 | 2008-07-10 | Pfizer Prod Inc | Proline derivatives and their use as dipeptidyl peptidase iv inhibitors |
US7214702B2 (en) | 2004-05-25 | 2007-05-08 | Bristol-Myers Squibb Company | Process for producing a dipeptidyl peptidase IV inhibitor |
TWI415635B (zh) | 2004-05-28 | 2013-11-21 | 必治妥施貴寶公司 | 加衣錠片調製物及製備彼之方法 |
WO2005117861A1 (en) | 2004-06-04 | 2005-12-15 | Novartis Ag | Use of organic compounds |
US7393836B2 (en) | 2004-07-06 | 2008-07-01 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
CA2572149A1 (en) | 2004-07-08 | 2006-01-19 | Astellas Pharma Inc. | Process for production of azulene derivatives and intermediates for the synthesis of the same |
CA2573209A1 (en) | 2004-07-14 | 2006-01-19 | Novartis Ag | Combination of dpp-iv inhibitors and compounds modulating 5-ht3 and/or 5-ht4 receptors |
DE102004034690A1 (de) | 2004-07-17 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
TW200606129A (en) | 2004-07-26 | 2006-02-16 | Chugai Pharmaceutical Co Ltd | Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same |
EP1773800A1 (de) | 2004-07-27 | 2007-04-18 | Boehringer Ingelheim International GmbH | D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
WO2006018150A1 (de) | 2004-08-11 | 2006-02-23 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
DE102004043944A1 (de) | 2004-09-11 | 2006-03-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
DE102004044221A1 (de) | 2004-09-14 | 2006-03-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
AR051446A1 (es) | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
DE102004048388A1 (de) | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
MX2007004305A (es) | 2004-10-12 | 2007-06-18 | Glenmark Pharmaceuticals Sa | Inhibidores novedosos de dipeptidil peptidasa iv, composiciones farmaceuticas que los contienen y procedimientos para su preparacion. |
AU2005299808B2 (en) | 2004-10-25 | 2009-08-20 | Novartis Ag | Combination of DPP-IV inhibitor, PPAR antidiabetic and metformin |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
EP1828216B1 (en) | 2004-12-16 | 2008-09-10 | Boehringer Ingelheim International GmbH | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
DE102004063099B4 (de) | 2004-12-22 | 2009-02-12 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von Thiophenglycosidderivaten |
BRPI0518651A2 (pt) | 2004-12-24 | 2008-12-02 | Dainippon Sumitomo Pharma | composto, uma prà-droga do mesmo, ou um sal do composto ou prà-droga farmaceuticamente aceitÁvel, composiÇço farmacÊutica, inibidor de dipeptidil peptidase iv, uso de um composto, uma prà-droga do mesmo ou um sal do composto ou prà-droga farmaceuticamente aceitÁvel, e, mÉtodo para tratar diabetes |
DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
GT200600008A (es) | 2005-01-18 | 2006-08-09 | Formulacion de compresion directa y proceso | |
TW200637869A (en) | 2005-01-28 | 2006-11-01 | Chugai Pharmaceutical Co Ltd | The spiroketal derivatives and the use as therapeutical agent for diabetes of the same |
ES2334940T3 (es) | 2005-02-23 | 2010-03-17 | Boehringer Ingelheim International Gmbh | Derivados de ((hetero)ariletinilbencil)benceno sustituidos con glucopiranosilo y uso de los mismos como inhibidores del cotransportador 2 de glucosa dependiente de sodio (sglt2). |
MX2007011546A (es) | 2005-03-22 | 2007-10-19 | Hoffmann La Roche | Nueva sal y polimorfos del inhibidor de dipeptidil-peptidasa iv. |
EP1874787B1 (en) | 2005-04-15 | 2009-12-30 | Boehringer Ingelheim International GmbH | Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors |
UA91546C2 (uk) | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
GT200600218A (es) | 2005-06-10 | 2007-03-28 | Formulación y proceso de compresión directa | |
MY152185A (en) | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
WO2007000445A1 (en) | 2005-06-29 | 2007-01-04 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
WO2007014894A2 (en) | 2005-07-27 | 2007-02-08 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted ( (hetero) cycloalyklethynyl-benzyl) -benzene derivatives and use thereof as sodium-dependent glucose cotransporter (sglt) inhibitors |
UY29694A1 (es) | 2005-07-28 | 2007-02-28 | Boehringer Ingelheim Int | Metodos para prevenir y tratar trastornos metabolicos y nuevos derivados de pirazol-o-glucosido |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
MX2008001609A (es) | 2005-08-04 | 2008-02-19 | Novartis Ag | Sales de vildagliptina. |
CN101232873A (zh) | 2005-08-11 | 2008-07-30 | 霍夫曼-拉罗奇有限公司 | 含有dpp-iv抑制剂的药物组合物 |
CA2620566A1 (en) | 2005-08-30 | 2007-03-08 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
ATE491700T1 (de) | 2005-09-08 | 2011-01-15 | Boehringer Ingelheim Int | KRISTALLINE FORMEN VON 1-CHLORO-4-(ß-D- |
PL1931350T5 (pl) | 2005-09-14 | 2021-11-15 | Takeda Pharmaceutical Company Limited | Podanie inhibitorów dipeptydylo-peptydazy |
DK1942898T4 (da) * | 2005-09-14 | 2014-06-02 | Takeda Pharmaceutical | Dipeptidylpeptidase-inhibitorer til behandling af diabetes |
AR056195A1 (es) | 2005-09-15 | 2007-09-26 | Boehringer Ingelheim Int | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos |
KR101368988B1 (ko) | 2005-09-16 | 2014-02-28 | 다케다 야쿠힌 고교 가부시키가이샤 | 디펩티딜 펩티다제 억제제 |
TW200745079A (en) | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor |
AU2006292377B2 (en) | 2005-09-20 | 2011-03-03 | Emisphere Technologies, Inc. | Use of a DPP-IV inhibitor to reduce hypoglycemic events |
JOP20180109A1 (ar) | 2005-09-29 | 2019-01-30 | Novartis Ag | تركيبة جديدة |
US20090156579A1 (en) | 2005-10-25 | 2009-06-18 | Hasegawa Philip A | Combination of a Dipeptidyl Peptidase-4 Inhibitor and an Anti-Hypertensive Agent for the Treatment of Diabetes and Hypertension |
BRPI0620718A2 (pt) | 2005-10-28 | 2011-11-22 | Takeda Pharmaceutical | agente para a proteção do páncreas, e, uso de uma droga para a redução de glicose |
EP1785745A1 (de) | 2005-11-10 | 2007-05-16 | Omron Electronics Manufacturing of Germany GmbH | Verfahren und Bedieneinheit zum Konfigurieren und Überwachen einer Einrichtung mit funktionaler Sicherheit |
CN101365432B (zh) | 2005-12-16 | 2011-06-22 | 默沙东公司 | 二肽基肽酶-4抑制剂与二甲双胍的组合的药物组合物 |
CN101341148A (zh) | 2005-12-21 | 2009-01-07 | 霍夫曼-拉罗奇有限公司 | 新型的dpp-iv抑制剂的盐和多晶型物 |
CN101384594A (zh) | 2005-12-23 | 2009-03-11 | 诺瓦提斯公司 | 用作dpp-iv抑制剂的稠合杂环化合物 |
WO2007120936A2 (en) | 2006-01-06 | 2007-10-25 | Novartis Ag | Use.of vildagliptin for the treatment of diabetes |
CA2635838A1 (en) | 2006-02-15 | 2007-08-23 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
JP2009531456A (ja) | 2006-03-28 | 2009-09-03 | 武田薬品工業株式会社 | (r)−3−アミノピペリジン二塩酸塩の調製 |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
NO347644B1 (no) | 2006-05-04 | 2024-02-12 | Boehringer Ingelheim Int | Polymorfer |
KR20070111099A (ko) | 2006-05-16 | 2007-11-21 | 영진약품공업주식회사 | 시타글립틴 염산염의 신규 결정형, 이의 제조 방법과 이를포함하는 약학적 조성물 |
CA2654890C (en) | 2006-06-16 | 2015-10-06 | Lek Pharmaceuticals D.D. | Pharmaceutical composition |
WO2007149797A2 (en) | 2006-06-19 | 2007-12-27 | Novartis Ag | Use of organic compounds |
WO2007148185A2 (en) | 2006-06-21 | 2007-12-27 | Pfizer Products Inc. | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors |
EP2035395A2 (en) | 2006-06-27 | 2009-03-18 | Glenmark Pharmaceuticals S.A. | Novel processes for the preparation of dpp iv inhibitors |
JP2010500326A (ja) | 2006-08-08 | 2010-01-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病の治療のためのdpp−iv阻害剤としてのピロロ[3,2−d]ピリミジン |
US8039441B2 (en) | 2006-08-15 | 2011-10-18 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture |
PE20081150A1 (es) | 2006-09-13 | 2008-10-03 | Takeda Pharmaceutical | Inhibidores de dipetidilpeptidasa |
WO2008031750A2 (en) | 2006-09-15 | 2008-03-20 | F. Hoffmann-La Roche Ag | Process for the preparation of pyrido[2,1-a]isoquinoline derivatives by catalytic asymmetric hydrogenation of an enamine |
CN101516880B (zh) | 2006-09-15 | 2012-06-20 | 霍夫曼-拉罗奇有限公司 | 包括烯胺的旋光拆分的用于制备吡啶并[2,1-a]异喹啉衍生物的方法 |
WO2008034859A1 (en) | 2006-09-21 | 2008-03-27 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
US8283326B2 (en) | 2006-10-27 | 2012-10-09 | Boehringer Ingelheim International Gmbh | Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
US7956201B2 (en) | 2006-11-06 | 2011-06-07 | Hoffman-La Roche Inc. | Process for the preparation of (S)-4-fluoromethyl-dihydro-furan-2-one |
CA2668623A1 (en) | 2006-11-06 | 2008-05-15 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture |
BRPI0718596B8 (pt) * | 2006-11-09 | 2021-05-25 | Boehringer Ingelheim Int | composições farmacêuticas para terapia de combinação com inibidores de sglt-2 e metformina |
WO2008062273A2 (en) | 2006-11-20 | 2008-05-29 | Cadila Pharmaceuticals Limited | Solid oral dosage form having antidiabetic drug combination |
US20100081625A1 (en) | 2007-01-26 | 2010-04-01 | Boehringer Ingelheim International Gmbh | Methods for preventing and treating neurodegenerative disorders |
WO2008089892A1 (de) | 2007-01-26 | 2008-07-31 | Sanofi-Aventis | Phenothiazin derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
PL2107905T3 (pl) | 2007-02-01 | 2011-04-29 | Takeda Pharmaceuticals Co | Stały preparat zawierający alogliptynę i pioglitazon |
ES2639854T3 (es) | 2007-02-01 | 2017-10-30 | Takeda Pharmaceutical Company Limited | Preparación de comprimidos sin causar problemas de fabricación de comprimidos |
ITFI20070042A1 (it) | 2007-02-21 | 2008-08-22 | Laboratori Guidotti Spa | Formulazione farmaceutica e compressa comprendente detta formulazione. |
WO2008101939A1 (en) | 2007-02-21 | 2008-08-28 | Boehringer Ingelheim International Gmbh | Tetrasubstituted glucopyranosylated benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
WO2008101938A1 (en) | 2007-02-21 | 2008-08-28 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture |
WO2008113000A1 (en) | 2007-03-15 | 2008-09-18 | Nectid, Inc. | Anti-diabetic combinations comprising a slow release biguanide composition and an immediate release dipeptidyl peptidase iv inhibitor composition |
PE20090185A1 (es) | 2007-03-22 | 2009-02-28 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
TW200904454A (en) | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof |
WO2008120813A1 (ja) | 2007-04-03 | 2008-10-09 | Mitsubishi Tanabe Pharma Corporation | ジペプチジルペプチダーゼ4阻害化合物と甘味料との併用 |
PE20090696A1 (es) | 2007-04-20 | 2009-06-20 | Bristol Myers Squibb Co | Formas cristalinas de saxagliptina y procesos para preparar las mismas |
CN101754972A (zh) | 2007-05-18 | 2010-06-23 | 百时美施贵宝公司 | Sglt2抑制剂的晶体结构及其制备方法 |
FR2920023B1 (fr) | 2007-08-16 | 2013-02-08 | Sanofi Aventis | Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique |
CL2008002425A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta. |
UY31290A1 (es) | 2007-08-16 | 2009-03-31 | Composicion farmacéutica que comprende un derivado de pirazol-o-glucosido | |
CL2008002427A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
UY31291A1 (es) | 2007-08-16 | 2009-03-31 | Composicion farmacéutica que comprende un derivado de pirazol-0-glucosido | |
WO2009024542A2 (en) | 2007-08-17 | 2009-02-26 | Boehringer Ingelheim International Gmbh | Purin derivatives for use in the treatment of fab-related diseases |
UA105480C2 (uk) | 2007-09-10 | 2014-05-26 | Янссен Фармацевтика Н.В. | Спосіб одержання сполук, які застосовують як інгібітори натрійзалежного переносника глюкози |
CA2705821A1 (en) | 2007-11-16 | 2009-05-22 | Novo Nordisk A/S | Pharmaceutical compositions containing insulin and an insulinotropic peptide |
CN101234105A (zh) | 2008-01-09 | 2008-08-06 | 北京润德康医药技术有限公司 | 一种含有二甲双胍和维格列汀的药用组合物及其制备方法 |
CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
AU2009210641A1 (en) | 2008-02-05 | 2009-08-13 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-IV inhibitor |
US8551524B2 (en) | 2008-03-14 | 2013-10-08 | Iycus, Llc | Anti-diabetic combinations |
CL2009000782A1 (es) | 2008-03-31 | 2010-04-30 | Metabolex Inc | Metodo que comprende un compuesto derivado de oximetilen-arilo sustituido, inhibidores de dpp-iv; y su uso en el tratamiento de la diabetes y disminucion de trigliceridos, entre otras enfermedades. |
AR071175A1 (es) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante |
PE20100156A1 (es) | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
BRPI0917675A2 (pt) | 2008-08-15 | 2015-12-01 | Boehringer Ingelheim Int | compostos orgânicos para cura de ferida |
MX2011002558A (es) | 2008-09-10 | 2011-04-26 | Boehringer Ingelheim Int | Terapia de combinacion para el tratamiento de diabetes y estados relacionados. |
UY32177A (es) | 2008-10-16 | 2010-05-31 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético |
WO2010045656A2 (en) | 2008-10-17 | 2010-04-22 | Nectid, Inc. | Novel sglt2 inhibitor dosage forms |
US8865729B2 (en) | 2008-12-23 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Salt forms of a xanthine compound |
TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
AR075204A1 (es) | 2009-01-29 | 2011-03-16 | Boehringer Ingelheim Int | Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2 |
CN106177958A (zh) | 2009-02-13 | 2016-12-07 | 勃林格殷格翰国际有限公司 | 包含dpp‑4抑制剂(利拉列汀)任选地组合其它抗糖尿病药的抗糖尿病药物 |
KR101921934B1 (ko) | 2009-02-13 | 2018-11-26 | 베링거 인겔하임 인터내셔날 게엠베하 | 글루코피라노실 디페닐메탄 유도체를 포함하는 약제학적 조성물, 이들의 약제학적 용량형, 이들의 제조방법 및 환자에서의 개선된 당 조절을 위한 이들의 용도 |
CN104906582A (zh) | 2009-02-13 | 2015-09-16 | 勃林格殷格翰国际有限公司 | 包含sglt2抑制剂、dpp-iv抑制剂和任选的另一种抗糖尿病药的药物组合物及其用途 |
UY32427A (es) | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
MA33043B1 (fr) | 2009-02-13 | 2012-02-01 | Boehringer Ingelheim Int | Inhibiteur sglt-2 pour le traitement du diabete sucre de type 1, du diabete sucre de type 2, d'une intolerance au glucose ou d'une hyperglycemie |
CN102639125A (zh) | 2009-05-27 | 2012-08-15 | 百时美施贵宝公司 | 使用sglt2抑制剂及其组合物在对先前用其它抗糖尿病药进行的治疗具有耐受的患者中治疗ii型糖尿病的方法 |
AU2010260373A1 (en) | 2009-06-15 | 2012-01-12 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone |
EP2486029B1 (en) | 2009-09-30 | 2015-06-10 | Boehringer Ingelheim International GmbH | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives |
CA2775961C (en) | 2009-09-30 | 2017-11-07 | Boehringer Ingelheim International Gmbh | Method for the preparation of a crystalline form of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene |
UY32919A (es) | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos |
EP4209210A1 (en) | 2009-10-02 | 2023-07-12 | Boehringer Ingelheim International GmbH | Pharmaceutical compositions comprising bi-1356 and metformin |
CA2780941C (en) | 2009-11-13 | 2018-06-12 | Bristol-Myers Squibb Company | Immediate release tablet formulations |
AU2010323068B2 (en) | 2009-11-27 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
WO2011113947A1 (en) | 2010-03-18 | 2011-09-22 | Boehringer Ingelheim International Gmbh | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
EP2368552A1 (en) | 2010-03-25 | 2011-09-28 | Boehringer Ingelheim Vetmedica GmbH | 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(r)-amino-piperidin-1-yl]-xanthine for the treatment of a metabolic disorder of a predominantly carnivorous non-human animal |
WO2011120923A1 (en) | 2010-03-30 | 2011-10-06 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof |
CN102883711A (zh) | 2010-05-05 | 2013-01-16 | 贝林格尔.英格海姆国际有限公司 | 包含吡格列酮和利格列汀的药物组合物 |
WO2011138421A1 (en) | 2010-05-05 | 2011-11-10 | Boehringer Ingelheim International Gmbh | Combination therapy |
KR20190050871A (ko) | 2010-06-24 | 2019-05-13 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
US20120283169A1 (en) | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
US20130035281A1 (en) | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
US20130035298A1 (en) | 2011-07-08 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
-
2008
- 2008-08-14 CL CL2008002427A patent/CL2008002427A1/es unknown
- 2008-08-14 PE PE2008001382A patent/PE20090938A1/es active IP Right Grant
- 2008-08-15 CN CN201410482945.1A patent/CN104353077A/zh active Pending
- 2008-08-15 PL PL08787264T patent/PL2187879T3/pl unknown
- 2008-08-15 MY MYPI20100681 patent/MY152037A/en unknown
- 2008-08-15 MX MX2010001696A patent/MX2010001696A/es active IP Right Grant
- 2008-08-15 CN CN201410482423.1A patent/CN104288166A/zh active Pending
- 2008-08-15 LT LTEP08787264.4T patent/LT2187879T/lt unknown
- 2008-08-15 ES ES08787264.4T patent/ES2602748T3/es active Active
- 2008-08-15 EP EP21189804.4A patent/EP3939577A1/en active Pending
- 2008-08-15 CN CN200880102911A patent/CN101784270A/zh active Pending
- 2008-08-15 UY UY31296A patent/UY31296A1/es active IP Right Grant
- 2008-08-15 ME MEP-2016-255A patent/ME02573B/me unknown
- 2008-08-15 SI SI200831745A patent/SI2187879T1/sl unknown
- 2008-08-15 TW TW103116634A patent/TW201436798A/zh unknown
- 2008-08-15 BR BRPI0815331A patent/BRPI0815331B8/pt active IP Right Grant
- 2008-08-15 EA EA201000321A patent/EA018608B1/ru active Protection Beyond IP Right Term
- 2008-08-15 TW TW97131324A patent/TWI472325B/zh active
- 2008-08-15 RS RS20160963A patent/RS55205B1/sr unknown
- 2008-08-15 JP JP2010520594A patent/JP5595914B2/ja active Active
- 2008-08-15 NZ NZ583242A patent/NZ583242A/xx unknown
- 2008-08-15 WO PCT/EP2008/060736 patent/WO2009022007A1/en active Application Filing
- 2008-08-15 DK DK08787264.4T patent/DK2187879T3/en active
- 2008-08-15 US US12/673,327 patent/US8551957B2/en active Active
- 2008-08-15 AR ARP080103592A patent/AR067970A1/es not_active Application Discontinuation
- 2008-08-15 AU AU2008288407A patent/AU2008288407B2/en active Active
- 2008-08-15 EP EP16172707.8A patent/EP3106156A1/en not_active Withdrawn
- 2008-08-15 EP EP13180262.1A patent/EP2698152A1/en not_active Withdrawn
- 2008-08-15 EP EP08787264.4A patent/EP2187879B1/en active Active
- 2008-08-15 KR KR20107003411A patent/KR101491554B1/ko active IP Right Review Request
- 2008-08-15 PT PT87872644T patent/PT2187879T/pt unknown
- 2008-08-15 HU HUE08787264A patent/HUE030158T2/hu unknown
- 2008-08-15 UA UAA201002970A patent/UA100384C2/ru unknown
- 2008-08-15 CA CA2696558A patent/CA2696558C/en active Active
-
2009
- 2009-12-21 ZA ZA200909105A patent/ZA200909105B/xx unknown
- 2009-12-22 IL IL202886A patent/IL202886A/en active IP Right Grant
-
2010
- 2010-02-05 CO CO10012795A patent/CO6251239A2/es active IP Right Grant
- 2010-02-12 TN TNP2010000073A patent/TN2010000073A1/fr unknown
- 2010-02-15 MA MA32622A patent/MA31612B1/fr unknown
- 2010-02-19 EC EC2010009977A patent/ECSP109977A/es unknown
- 2010-11-11 HK HK15102815.2A patent/HK1203351A1/xx unknown
- 2010-11-11 HK HK15101597.8A patent/HK1201721A1/xx unknown
-
2012
- 2012-08-23 AR ARP120103117A patent/AR087657A2/es not_active Application Discontinuation
-
2016
- 2016-12-09 CY CY20161101277T patent/CY1118308T1/el unknown
-
2017
- 2017-01-09 HR HRP20170022TT patent/HRP20170022T1/hr unknown
- 2017-05-05 NO NO2017020C patent/NO2017020I2/no unknown
- 2017-05-08 NL NL300872C patent/NL300872I2/nl unknown
- 2017-05-08 LT LTPA2017014C patent/LTC2187879I2/lt unknown
- 2017-05-09 CY CY2017017C patent/CY2017017I1/el unknown
- 2017-05-10 HU HUS1700020C patent/HUS1700020I1/hu unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2187879T3 (en) | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative. | |
US12115179B2 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
US20130096076A1 (en) | Pharmaceutical composition comprising a sglt2 inhibitor in combination with a dpp-iv inhibitor | |
WO2009022008A1 (en) | Pharmaceutical composition comprising a pyrazole-o-glucoside derivative | |
DK2672966T3 (en) | Pharmaceutical composition, methods of treatment and uses thereof. | |
EP3362055B1 (en) | Sglt-2 inhibitor for use in the treatment of a metabolic myopathy | |
EP2729151B1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
US20140088027A1 (en) | Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof | |
JP2010536734A6 (ja) | Dpp iv阻害剤と併用するsglt2阻害剤を含む医薬組成物 | |
WO2009022009A1 (en) | Pharmaceutical composition comprising a pyrazole-o-glucoside derivative |